---
title: "Guizhou Yibai Pharmaceutical Co.,Ltd. (600594.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600594.SH.md"
symbol: "600594.SH"
name: "Guizhou Yibai Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T08:58:12.677Z"
locales:
  - [en](https://longbridge.com/en/quote/600594.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600594.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600594.SH.md)
---

# Guizhou Yibai Pharmaceutical Co.,Ltd. (600594.SH)

## Company Overview

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatic bone, digestive system, pediatric, anti-infection, anti-inflammatory, analgesic, cancer, orthopedics, digestion, andrology, and urology. The company also engages in investment in the cultivation and breeding projects of medicinal materials; and agricultural products sale, as well as provides market information consulting services for medicinal materials.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.gzcci.com](https://www.gzcci.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: D (0.64)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 204 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -18.19% |  |
| Net Profit YoY | -35.47% |  |
| P/B Ratio | 1.44 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3109877142.08 |  |
| Revenue | 1723336982.39 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -15.08% | E |
| Profit Margin | -20.33% | D |
| Gross Margin | 57.92% | B |
| Revenue YoY | -18.19% | E |
| Net Profit YoY | -35.47% | D |
| Total Assets YoY | -14.94% | E |
| Net Assets YoY | -13.61% | E |
| Cash Flow Margin | -84.17% | E |
| OCF YoY | -18.19% | E |
| Turnover | 0.47 | C |
| Gearing Ratio | 34.03% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Guizhou Yibai Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-18.19%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-35.47%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.44",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3109877142.08",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1723336982.39",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-15.08%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-20.33%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "57.92%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-18.19%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-35.47%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-14.94%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-13.61%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-84.17%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-18.19%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.47",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "34.03%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.88 | 174/215 | - | - | - |
| PB | 1.44 | 34/215 | 1.43 | 1.35 | 1.30 |
| PS (TTM) | 1.80 | 29/215 | 1.79 | 1.69 | 1.58 |
| Dividend Yield | 0.00% | - | 1.70% | 1.68% | 1.68% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600594.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600594.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600594.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600594.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**